Clinical Research Trials
Retinal diseases are a leading cause of vision loss and blindness, affecting millions of people worldwide. Clinical trials are vital to the development of new treatments and therapies for these conditions, and there are many ongoing trials testing promising new approaches.
Star Retina is proud to take part in clinical research trials for many common retinal conditions. Below are trials for which we are currently enrolling new patients and those that have been completed.
Open Trials
Sponsor: OcuTerra-OTT 166-201 DREAM OTT166-201
A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy
(DR)
Sponsor: ORA Cognition Therapeutics (PILL STUDY)
A Randomized, Double-Masked, Placebo-controlled, Parallel group, Phrase 2 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants with Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).
ETA:<DECEMBER
Sponsor: RegenexBio ATMOSPHERE
a randomized partially masked controlled clinical study to evaluate the efficacy and safety of RGX-314 Gene Therapy in participants with nAMD. Lucentis Sponsor: RegenxBio ASCENT
a randomized partially masked controlled clinical study to evaluate the efficacy and safety of RGX-314 Gene Therapy in participants with nAMD. Eyela Sponsor: Opthea OPT-302-1005 COAST Eyela OPT-302-1005-COAST
A Phase 3, Multicentre, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
Closed Trials
Sponsor: KODIAK GLEAM
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)
ETA: CLOSED
Sponsor: KODIAK GLOW A Prospective, Randomized, Double-masked, Active Comparatorcontrolled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)ETA: CLOSED
Sponsor: ORA ANX007-GA-0 A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Geographic Atrophy (GA)ETA: CLOSED
Sponsor: KODIAK Daylight A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Neovascular (Wet) Age-related Macular Degeneration (wAMD) (DAYLIGHT)ETA: CLOSED
For referring doctors or patients who wish to learn more about our research protocols or activities, please continue reading below or contact our office at 817-378-4777
